Long Ideas - Following news that Elan’s (NASDAQ:ELN) developmental Alzheimer’s treatment, bapineuzumab, failed a Phase III trial in August and was subsequently discontinued, PropThink advised a position in … Continue Reading
Read nowLong Ideas - Delcath Systems (NADSAQ:DCTH) continues to trade well-above average volume Tuesday, ahead of the FDA’s decision on the company’s recently submitted New Drug Application (NDA) for … Continue Reading
Read now- By Jake King In a press release Monday, BioSante Pharmaceuticals (NASDAQ:BPAX) announced that it will be presenting a corporate update at the BIO Investor Forum … Continue Reading
Read nowLong Ideas - By Jake King Spectrum Pharmaceuticals (NASDAQ:SPPI) announced Monday morning that the company received a five-year extension on its patent for Folotyn, which lengthens the drug’s … Continue Reading
Read nowMost Popular - We continued to add to our Interview collection, posting discussions this past week with the CEO’s of both AdventRx Pharmaceuticals and ARIAD Pharmaceuticals. Our final … Continue Reading
Read nowLong Ideas - Ventrus Biosciences (NASDAQ:VTUS) recently hired JP Benya as its new VP of Commercial Operations and Business Development, with the intent that Benya will play a … Continue Reading
Read nowLong Ideas - Celgene (NASDAQ:CELG) moved closer today to securing another indication for its oncology drug, Abraxane, which is already approved as a second-line treatment for metastatic breast … Continue Reading
Read now